Optimizing the Precision Oncology Workflow at a Public Safety-Net Cancer Center

Authors

  • Kevin Diasti Division of Hematology and Medical Oncology, Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY and Bellevue Cancer Center, NYC Health + Hospitals/Bellevue Hospital Center, New York, NY
  • Peter Yu Division of Hematology and Medical Oncology, Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY and Bellevue Cancer Center, NYC Health + Hospitals/Bellevue Hospital Center, New York, NY
  • Gaurav Varma Division of Hematology and Medical Oncology, Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY and Bellevue Cancer Center, NYC Health + Hospitals/Bellevue Hospital Center, New York, NY
  • Ahan Bhatt Bellevue Cancer Center, NYC Health + Hospitals/Bellevue Hospital Center, New York, NY, NYC Health + Hospitals/Jacobi Medical Center, Bronx, NY and Albert Einstein College of Medicine, Bronx, NY
  • Jennifer Wu Division of Hematology and Medical Oncology, Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY and Bellevue Cancer Center, NYC Health + Hospitals/Bellevue Hospital Center, New York, NY

DOI:

https://doi.org/10.14738/bjhr.1201.18363

Abstract

Background: Comprehensive tumor molecular profiling using next-generation sequencing (NGS) enables personalized cancer treatment and is standard of care in the management of advanced solid malignancies. Given challenges with efficient implementation of NGS testing in safety-net health care settings, we evaluated the tissue NGS workflow at our facility and investigated the impact of a targeted specimen courier service intervention. Methods: We constructed a NGS workflow process map to identify key stakeholders and potential sources of delays. 26 clinicians were surveyed regarding time spent placing orders, reliance on a process guide sheet, and adherence to key steps in the ordering process. Utilization and process data from 2019-2022 was obtained from our NGS vendor. Time from order placement to result report [Turn Around Time; (TAT)] was the primary process measure; secondary measures were time from order placement to specimen receipt by the vendor [Order to Specimen (OTS)] and time from specimen receipt to reporting of results [Specimen to Report (STR)]. Medians for TAT, OTS, and STR were compared over 3-month intervals, and pre- and post-courier service implementation. A Root Cause Analysis was conducted to identify additional delays and opportunities for further optimization. Results: Between 2019 and 2022 median TAT was 22 days, with a downward trend in median TAT to 18.5 days at the end of 2022. Median OTS and TAT were significantly improved following courier service introduction (13 vs 7 days and 23 vs. 18.5 days, respectively). STR remained stable throughout the periods of interest. Only 63.6%-72.7% of clinicians reported correctly completing key steps of the ordering workflow possibly contributing to delays in OTS and TAT. Conclusions: We assessed the complex effort of optimizing the NGS testing workflow at a large safety-net health system. Courier service implementation improved OTS and overall TAT. Surveys identified inefficiencies in the provider side of the ordering process. Future opportunities to improve TAT include NGS order integration with electronic medical systems.

References

Ossowski S, Neeman E, Borden C, et al: Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small-Cell Lung Cancer. JCO Oncol Pract 18:e1874–e1884, 2022

Our Model [Internet][cited 2024 Apr 15] Available from: https://about.kaiserpermanente.org/commitments-and-impact/public-policy/integrated-care

Lau-Min KS, McKenna D, Asher SB, et al: Impact of Integrating Genomic Data into the Electronic Health Record on Genetics Care Delivery. Genet Med 24:2338–2350, 2022

Vidal GA, Jain N, Fisher A, et al: Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncol Pract 20:370–377, 2024

Shi R, Taylor H, McLarty J, et al: Effects of payer status on breast cancer survival: a retrospective study. BMC Cancer 15:211, 2015

Shi L, Suh W, Kavanaugh MM, et al: Propensity Score Matching Analysis of the Effect of Payer Status on the Survival of Colon Cancer Patients. Cureus 13:e15748, 2021

Espinoza-Gutarra MR, Duma N, Aristizabal P, et al: The Problem of Hispanic/Latinx Under-Representation in Cancer Clinical Trials. JCO Oncol Pract 18:380–384, 2022

Community Health Needs Assessment - net. nychealthandhospitals.org. (2022, June 30). https://hhinternet.blob.core.windows.net/uploads/2022/07/community-health-needs-asssessment-2022.pdf

Bellevue Hospital Center. nychealthandhospitals.org. (2013, May 30). https://www.nychealthandhospitals.org/wp-content/uploads/2016/07/chna-bellevue-2013.pdf

Kurian AW, Li Y, Hamilton AS, et al: Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. J Clin Oncol 35:2232–2239, 2017

Downloads

Published

2025-02-25

How to Cite

Diasti, K., Yu, P., Varma, G., Bhatt, A., & Wu, J. (2025). Optimizing the Precision Oncology Workflow at a Public Safety-Net Cancer Center. British Journal of Healthcare and Medical Research, 12(01), 354–361. https://doi.org/10.14738/bjhr.1201.18363